Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Sequencing in BRCA-Positive TNBC Patients

February 15th 2018

NCCN Guideline Changes for BRCA Testing in TNBC

February 15th 2018

Germline BRCA Mutations in TNBC

February 15th 2018

Histologic Subtyping in TNBC

February 15th 2018

Classification of Triple Negative Breast Cancer

February 15th 2018

Network Enlists Practicing Oncologists to Develop Plans

February 3rd 2018

Physicians are carefully evaluating potential partnership and referral deals to ensure that whatever they do is perceived as aligned with delivering better, more efficient care.

Dr. Raz on the Impact of the ALCHEMIST Trial on the Treatment of Patients With Lung Cancer

January 31st 2018

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

Biomarkers Go Beyond "All or None" Equation

January 31st 2018

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

Promising Immunotherapy Approaches in AML

January 19th 2018

Promising Targeted Approaches in AML

January 19th 2018

Defining the Challenges of FLT3 Inhibition in AML

January 19th 2018

Emerging FLT3 Inhibitors in AML

January 19th 2018

Second-Generation FLT3 Inhibitors in AML: Quizartinib

January 19th 2018

MRD's Potential Role in Treating Acute Myeloid Leukemia

January 19th 2018

Treating CD33-Positive AML With Gemtuzumab Ozogamicin

January 19th 2018

AML: Identifying Practical Concerns With Enasidenib

January 19th 2018

Enasidenib's Role in IDH-Mutant Acute Myeloid Leukemia

January 19th 2018

Considering Midostaurin for Acute Myeloid Leukemia

January 19th 2018

RATIFY Trial: Midostaurin's Role in Treating AML

January 19th 2018